

Applicants : Michael J. Elliott et al.
U.S. Serial No.: 08/602,272
Filed : February 16, 1996
Page 2

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1-5. (Canceled)

6. (Previously Presented) A method of treating thrombosis in a subject diagnosed as suffering from thrombosis comprising administering a therapeutically effective amount of an anti-tumor necrosis factor antibody or antigen-binding fragment thereof to the subject.

7-8. (Canceled)

9. (Previously Presented) The method of claim 6, wherein the antibody is selected from the group consisting of a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.

10. (Previously Presented) The method of claim 6, wherein the antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .

11. (Canceled)

12. (Previously Presented) The method of claim 6, wherein the antibody is a chimeric antibody, said chimeric antibody

Applicants : Michael J. Elliott et al.
U.S. Serial No.: 08/602,272
Filed : February 16, 1996
Page 3

comprising (a) a non-human variable region specific for TNF or an antigen-binding portion thereof and (b) a human constant region.

13. (Previously Presented) The method of claim 12, wherein the chimeric antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .

14. (Previously Presented) The method of claim 12, wherein the chimeric antibody is monoclonal antibody cA2.

15. (Previously Presented) The method of claim 12, wherein the chimeric antibody competitively inhibits binding of TNF α to monoclonal antibody cA2.

16-28. (Canceled)

29. (Previously Presented) A method of decreasing plasma fibrinogen in a subject diagnosed as suffering from thrombosis comprising administering a therapeutically effective amount of an anti-tumor necrosis factor antibody or antigen-binding fragment thereof to the subject.

30. (Canceled)

31. (Previously Presented) The method of claim 29, wherein the antibody is selected from the group consisting of a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.

Applicants : Michael J. Elliott et al.
U.S. Serial No.: 08/602,272
Filed : February 16, 1996
Page 4

32. (Previously Presented) The method of claim 29, wherein the antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .
33. (Canceled)
34. (Previously Presented) The method of claim 29, wherein the antibody is a chimeric antibody, said chimeric antibody comprising (a) a non-human variable region specific for TNF or an antigen-binding portion thereof and (b) a human constant region.
35. (Previously Presented) The method of claim 34, wherein the chimeric antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .
36. (Previously Presented) The method of claim 34, wherein the chimeric antibody competitively inhibits binding of TNF α to monoclonal antibody cA2.
37. (Previously Presented) The method of claim 34, wherein the chimeric antibody is monoclonal antibody cA2.
- 38-50. (Canceled)
51. (New) The method of claim 6, wherein the thrombosis is deep vein thrombosis.

Applicants : Michael J. Elliott et al.
U.S. Serial No.: 08/602,272
Filed : February 16, 1996
Page 5

52. (New) The method of claim 29, wherein the thrombosis is deep vein thrombosis.